Recombinant Human CUB domain-containing protein 1 (CDCP1), partial (Active)

In Stock
Code CSB-MP884474HU
MSDS
Size $318
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Activity
    Measured by its binding ability in a functional ELISA. Immobilized Human CDCP1 at 2μg/mL can bind Anti-CDCP1 recombinant antibody (CSB-RA884474MA1HU),the EC50 is 0.2943-0.4429 ng/mL. Biological Activity Assay
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 95% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human CDCP1 at 2 μg/mL can bind Anti-CDCP1 recombinant antibody (CSB-RA884474MA1HU), the EC50 is 0.2943-0.4429 ng/mL.
Target Names
Uniprot No.
Alternative Names
Membrane glycoprotein gp140; Subtractive immunization M plus HEp3-associated 135 kDa protein; SIMA135; Transmembrane and associated with src kinases
Species
Homo sapiens (Human)
Source
Mammalian cell
Expression Region
30-667aa
Target Protein Sequence
FEIALPRESNITVLIKLGTPTLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMSGPCPFGEVQLQPSTSLLPTLNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANYPEGFPEDELMTWQFVVPAHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDKQPGNMAGNFNLSLQGCDQDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIEPRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVEKTISCTDHRYCQRKSYSLQVPSDILHLPVELHDFSWKLLVPKDRLSLVLVPAQKLQQHTHEKPCNTSFSYLVASAIPSQDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSFQQEASRQGLTVSFIPYFKEEGVFTVTPDTKSKVYLRTPNWDRGLPSLTSVSWNISVPRDQVACLTFFKERSGVVCQTGRAFMIIQEQRTRAEEIFSLDEDVLPKPSFHHHSFWVNISNCSPTSGKQLDLLFSVTLTPRTVDLT
Mol. Weight
73.2 kDa
Protein Length
Partial
Tag Info
C-terminal 10xHis-tagged
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The recombinant human CDCP1 protein is synthesized using a mammalian cell expression system. By incorporating the human CDCP1 gene fragment (30-667aa) fused with a C-terminus 10xHis-tag gene into a plasmid vector, the construct is introduced into mammalian cells. Subsequent cell cultivation promotes efficient protein expression. SDS-PAGE analysis confirms the protein's purity surpassing 95%, while the LAL method verifies its low endotoxin levels below 1.0 EU/ug. The protein's functional activity is demonstrated by its interaction with CDCP1 recombinant antibody (CSB-RA884474MA1HU), with the EC50 of 0.2943-0.4429 ng/mL.

CDCP1 is limitedly expressed in normal human tissues but is upregulated in most cancers, including lung cancer, pancreatic cancer, renal cell carcinoma, ovarian cancer, and hepatocellular carcinoma, playing a pivotal role in the onset, progression, and relapse of tumors. The signaling pathways regulated by CDCP1 play a crucial role in promoting cancer and mediating resistance to chemotherapy and targeted therapies. Additionally, its associated antibodies demonstrate high affinity and specificity, making it a potential new target for early cancer treatment. Therefore, the development of CDCP1 protein can contribute to clinical drug development and research related to CDCP1.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May be involved in cell adhesion and cell matrix association. May play a role in the regulation of anchorage versus migration or proliferation versus differentiation via its phosphorylation. May be a novel marker for leukemia diagnosis and for immature hematopoietic stem cell subsets. Belongs to the tetraspanin web involved in tumor progression and metastasis.
Gene References into Functions
  1. Expression of CDCP1 was reduced by AHCC treatment of KLM1-R cells, whereas expression of actin was not affected. The ratio of intensities of CDCP1/actin in AHCC-treated KLM1-R cells was significantly suppressed (p<0.05) compared to untreated cells. PMID: 30396925
  2. Co-expression of CDCP1 and AXL is often observed in EGFR-mutation-positive tumors, limiting the efficacy of EGFR TKIs. Co-treatment with EGFR TKI and TPX-0005 warrants testing. PMID: 29433983
  3. CDCP1 knockdown reduced 3D invasion, which can be rescued by ACSL3 co-knockdown. In vivo, inhibiting CDCP1 activity with an engineered blocking fragment (extracellular portion of cleaved CDCP1) lead to increased LD abundance in primary tumors, decreased metastasis, and increased ACSL activity in two animal models of TNBC. PMID: 28739932
  4. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression. PMID: 28537886
  5. CDCP1 is a novel marker of the most aggressive N-positive triple-negative breast cancers; CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival PMID: 27626701
  6. High expression level of CDCP1 is associated with recurrence in glioblastoma. PMID: 26956052
  7. These studies have important implications for the development of a therapeutic to block CDCP1 activity and Triple-negative breast cancer (TNBC)metastasis. PMID: 26876198
  8. CDCP1 may facilitate loss of adhesion by promoting activation of EGFR and Src at sites of cell-cell and cell-substratum contact. PMID: 27495374
  9. Stromal expression patterns for both ADAM12 and CDCP1. PMID: 27685922
  10. these data demonstrated that HIF-2alpha could promote hepatocellular carcinoma cell migration by regulating CDCP1 PMID: 26307391
  11. Our results establish that differential glycosylation, cell surface presentation and extracellular expression of CDCP1 are hallmarks of prostate cancer progression. PMID: 26497208
  12. High CDCP1 expression is associated with Colorectal Cancer. PMID: 25820997
  13. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis PMID: 26553452
  14. Elevated CDCP1 was observed in 77% of HGSC cases. Silencing of CDCP1 reduced migration and non-adherent cell growth in vitro and tumour burden in vivo. PMID: 26882065
  15. CDCP1 protein plays an important role in the progression of ovarian clear cell carcinoma. Elevated CDCP1 levels correlates with poor patient outcome in ovarian clear cell carcinoma patients. PMID: 25893298
  16. CDCP1 overexpression enhances HER2 activity. CDCP1 binds to HER2, promoting SRC-HER2 crosstalk. PMID: 25892239
  17. Multiple tyrosine phosphorylation sites of CDCP1 are important for the functional regulation of SFKs in several tumor types. PMID: 25728678
  18. These data suggest CDCP1 expression can be used to identify a subset of marrow fibroblasts functionally distinct from CD146+ fibroblasts. PMID: 25275584
  19. The aim of this study was to examine whether activation of Trask may be potentially important in brain metastasis of lung cancers, the commonest site of organ spread and producing the deadliest consequences. PMID: 25775948
  20. decreased CDCP1 expression promoted the invasive and migratory abilities of esophageal cancer cell lines. PMID: 24849519
  21. CDCP1 protein induced by oncogenic Ras/Erk signaling is essential for Ras-mediated metastatic potential of cancer cells. PMID: 24939643
  22. CDCP1 modulates cell-substratum adhesion and motility in colon cancer cell lines. PMID: 25301083
  23. EGF increases the lifespan of CDCP1 promoting its availability on the cell surface where the data indicate it is available to mediate procancer phenotypes such as cell migration. PMID: 24681947
  24. CDCP1 is an essential regulator of the trafficking and function of MT1-MMP- and invadopodia-mediated invasion of cancer cells. PMID: 23439492
  25. CDCP1 represses the epithelial phenotype of pancreatic cancer cells. PMID: 24384474
  26. Complexing of beta1 integrin the 70-kDa with CDCP1 fragment induced intracellular phosphorylation signaling, involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation PMID: 23208492
  27. Expression and phosphorylation of exogenous CDCP1 by Fyn kinase reduced the formation of autophagosomes. PMID: 23510015
  28. In migrating cancer stem cells isolated from primary human colorectal cancers, CD110(+) and CDCP1(+) subpopulations mediate organ-specific lung and liver metastasis. PMID: 23747337
  29. strongly expressed in tumors derived from lung, colon, ovary, or kidney. for a full transformation capacity, the intact amino- and carboxy-termini of CDCP1 are essential. PMID: 23300860
  30. These data support a critical role for CDCP1 as a unique HIF-2alpha target gene involved in the regulation of cancer metastasis. PMID: 23378636
  31. Secreted CDCP1 can be a useful genetic marker for the diagnosis of metastatic prostate cancer. PMID: 22457534
  32. a novel role for CDCP1 in EGF/EGFR-induced cell migration and indicate that targeting of CDCP1 may be a rational approach to inhibit progression of cancers driven by EGFR signaling PMID: 22315226
  33. Data show that the signaling events that accompany the CDCP1 tyrosine phosphorylation observed in cell lines and lung tumors may explain how the CDCP1/SFK complex regulates motility and adhesion. PMID: 21725358
  34. Trask as one of several potential candidates for functionally relevant tumor suppressors on the 3p21.3 region of the genome frequently lost in human cancers. PMID: 21706059
  35. analysis of cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734 PMID: 21994943
  36. CDCP1 is selectively expressed in ovarian tumor vasculature PMID: 21617380
  37. CUB domain-containing protein 1 (CDCP1) is a substrate of Src family kinases and has been shown to regulate anoikis resistance, migration and matrix degradation during tumor invasion and metastasis in a tyrosine phosphorylation-dependent manner. Review. PMID: 21812858
  38. analysis of structural features of Trask that mediate its anti-adhesive functions PMID: 21559459
  39. Src-Trask signaling and Src-focal adhesion signaling inactivate each other, constituting two opposing modes of phosphotyrosine signaling that define a switch underlining cell anchorage state. PMID: 21490433
  40. Data provide molecular mechanisms for the metastasis-enhancing functions of CDCP1. PMID: 21220330
  41. Signal transduction from CDCP1 to PKCdelta leads to its activation, increasing migration of CC-RCC. Furthermore, patient survival can be stratified by CDCP1 expression at the cell surface of the tumor PMID: 21233420
  42. Trask signaling and focal adhesion signaling inactivate each other and signal in exclusion with each other, constituting a switch that underlies cell anchorage state. PMID: 21189288
  43. biological role of this protein and, potentially, its function in cancer, may be mediated by both 70-kDa cell retained and 65-kDa shed fragments, as well as the full-length 135-kDa protein. PMID: 20551327
  44. Overexpression of CDCP1 is associated with pancreatic cancers. PMID: 20501830
  45. In endometrioid adenocarcinoma low CDCP1 and advanced stage were independent poor prognostic factors for both overall and disease-free survival. PMID: 20372833
  46. findings indicate a functional role for CDCP1 in cancer and underscore the therapeutic potential of function-blocking anti-CDCP1 antibodies targeting both primary and metastatic carcinoma cells PMID: 19916495
  47. antibodies generated by subtractive immunization used to purify, identify and partially characterize SIMA135/CDCP1; properties indicate it is a multidomain cell surface antigen, highly expressed by certain cancer cells and normal and cancerous colon PMID: 12660814
  48. tyrosine phosphorylation of CDCP1 is regulated by adhesion or plasmin in epithelial cells PMID: 14739293
  49. CDCP1 is not only a novel marker for immature hematopoietic progenitor cell subsets but also unique in its property to recognize cells with phenotypes reminiscent of MSC and NPC. PMID: 15153610
  50. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat PMID: 16926850

Show More

Hide All

Subcellular Location
[Isoform 1]: Cell membrane; Single-pass membrane protein. Note=Shedding may also lead to a soluble peptide.; [Isoform 3]: Secreted.
Tissue Specificity
Highly expressed in mitotic cells with low expression during interphase. Detected at highest levels in skeletal muscle and colon with lower levels in kidney, small intestine, placenta and lung. Up-regulated in a number of human tumor cell lines, as well a
Database Links

HGNC: 24357

OMIM: 611735

KEGG: hsa:64866

STRING: 9606.ENSP00000296129

UniGene: Hs.476093

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*